Novavax (NVAX) Stock Price, News & Analysis

Company Overview

Novavax, Inc. is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus. In addition to its COVID-19 vaccine, Novavax is advancing candidates targeting respiratory syncytial virus (RSV) and seasonal influenza. These programs leverage the same nanoparticle and adjuvant technologies to address ongoing unmet needs in respiratory infectious disease.

Novavax operates globally, with research and development facilities in North America and manufacturing partnerships in Europe, Asia and Africa. Collaborations with organizations such as the Serum Institute of India and SK bioscience support its ability to supply vaccines in diverse markets. This international footprint enables the company to respond rapidly to public health emergencies and to pursue broad distribution of its products.

Under the leadership of President and Chief Executive Officer John C. Jacobs, who joined the company in 2021, Novavax has focused on scaling manufacturing capacity and securing regulatory approvals for its vaccine candidates. The company’s executive team and board include experienced professionals from the vaccine and biopharmaceutical industries, guiding its efforts to expand the global reach of its proprietary vaccine platform.

Key Stats

• Today's Range: $8.85 to $9.37
• 50-Day Range: $7.70 to $10.80
• 52-Week Range: $5.96 to $11.97
• Volume: 4.60 million shs
• Average Volume: 5.14 million shs
• Market Capitalization: $1.54 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.13
• Consensus Rating: Hold

Novavax Stock Analysis - MarketRank™

Novavax scored higher than 39% of companies evaluated by MarketBeat, and ranked 707th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Hold

Consensus Rating

Novavax has received a consensus rating of Hold. The company's average rating score is 2.10, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 4 sell ratings.

Upside Potential

Novavax has a consensus price target of $12.13, representing about 29.7% upside from its current price of $9.35.

Amount of Analyst Coverage

Novavax has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Novavax are expected to decrease in the coming year, from ($0.20) to ($0.31) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Novavax is -16.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Novavax is -16.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

30.39% of the float of Novavax has been sold short.

Short Interest Ratio / Days to Cover

Novavax has a short interest ratio ("days to cover") of 17.25, which indicates bearish sentiment.

Change versus previous month

Short interest in Novavax has recently increased by 6.77%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Novavax does not currently pay a dividend.

Dividend Growth

Novavax does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.69

News Sentiment

Novavax has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 22 news articles for Novavax this week, compared to 8 articles on an average week.

Search Interest

31 people have searched for NVAX on MarketBeat in the last 30 days. This is an increase of 182% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Novavax to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Novavax insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.00% of the stock of Novavax is held by insiders.

Percentage Held by Institutions

53.04% of the stock of Novavax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 5/14/2026
• Jefferies Global Healthcare Conference 2026: 6/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NVAX
• CIK: 1000694
• Web: www.novavax.com
• Phone: (240) 268-2000
• Fax: 240-268-2100
• Employees: 1,990
• Year Founded: 1987

Price Target and Rating

• Average Price Target for Novavax: $12.13
• High Price Target: $19.00
• Low Price Target: $6.00
• Potential Upside/Downside: +29.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.10
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $440.30 million
• Net Margins: -14.73%
• Pretax Margin: -14.45%
• Return on Equity: -14.82%
• Return on Assets: 1.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.48
• Quick Ratio: 2.45

Sales & Book Value

• Annual Sales: $1.12 billion
• Price / Sales: 1.37
• Cash Flow: $3.56 per share
• Price / Cash Flow: 2.63
• Book Value: ($0.88) per share
• Price / Book: -10.63

Miscellaneous

• Outstanding Shares: 164,440,000
• Free Float: 162,794,000
• Market Cap: $1.54 billion
• Optionable: Optionable
• Beta: 2.37